BAX (Baxter International) NonCurrent Deferred Revenue: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BAX Baxter International Inc BAX
69 GF Score
Price $25.93
GF Value $33.01
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Baxter International NonCurrent Deferred Revenue?

Baxter International BAX -2.15% 69 NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus rates BAX with a GF Score™ of 69/100 and a GF Value™ of $33.01 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Baxter International's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0 Mil.

Baxter International NonCurrent Deferred Revenue Related Terms

Baxter International NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Baxter International's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baxter International NonCurrent Deferred Revenue Chart

Baxter International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.00 40.00 41.00 40.00 36.00

Baxter International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 36.00 0.00 0.00
BAX
69GF Score
Baxter International Inc BAX
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0 Mil mean?
Baxter International (BAX) has a NonCurrent Deferred Revenue of $0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Baxter International and its competitors.
Is Baxter International's NonCurrent Deferred Revenue too high?
Baxter International's current NonCurrent Deferred Revenue is $0 Mil. Overall, Baxter International has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Baxter International's NonCurrent Deferred Revenue compare to ALGN and SOLV?
Baxter International's NonCurrent Deferred Revenue of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Devices & Instruments company?
A good NonCurrent Deferred Revenue depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Baxter International and its competitors. Baxter International's current NonCurrent Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (BAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $33.01, compared to a current price of $25.93 — trading 21.4% below its estimated fair value. The current NonCurrent Deferred Revenue is $0 Mil. Baxter International's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Baxter International (BAX), the current NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Baxter International (BAX) Overvalued in 2026?

Based on GuruFocus' analysis, Baxter International stock appears to be undervalued. The current stock price of $25.93 is trading 21.4% below its estimated GF Value™ of $33.01. GuruFocus considers Baxter International to be Modestly Undervalued.

Key valuation signals for BAX:

  • NonCurrent Deferred Revenue: $0 Mil
  • GF Value™: $33.01 vs. price of $25.93 (21.4% below fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Baxter International Business Description

Address One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
69GF Score

Get the complete analysis for BAX

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.93
Price
$33.01
GF Value